Paul Tudor Jones's FOLD Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 900,000 shares of Amicus Therapeutics, Inc. (FOLD) worth $12.82 M, representing 0.02% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in FOLD, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 731,016 shares. Largest reduction occurred in Q3 2019, reducing 186,971 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +731,016 | Add 432.59% | 900,000 | $14.24 |
| Q3 2025 | +9,487 | Add 5.95% | 168,984 | $7.88 |
| Q2 2025 | +88,206 | Add 123.73% | 159,497 | $5.73 |
| Q1 2025 | -77,577 | Reduce 52.11% | 71,291 | $8.16 |
| Q4 2024 | +514 | Add 0.35% | 148,868 | $9.42 |
| Q3 2024 | +148,354 | New Buy | 148,354 | $10.68 |
| Q2 2023 | -133,697 | Sold Out | 0 | $0.00 |
| Q1 2023 | +79,120 | Add 144.97% | 133,697 | $0.01 |
| Q4 2022 | +54,577 | New Buy | 54,577 | $0.01 |
| Q4 2021 | -12,579 | Sold Out | 0 | $0.00 |
| Q3 2021 | +12,579 | New Buy | 12,579 | $9.54 |
| Q2 2021 | -63,292 | Sold Out | 0 | $0.00 |
| Q1 2021 | +17,150 | Add 37.17% | 63,292 | $9.87 |
| Q4 2020 | +30,546 | Add 195.86% | 46,142 | $23.08 |
| Q3 2020 | +15,596 | New Buy | 15,596 | $14.11 |
| Q1 2020 | -49,156 | Sold Out | 0 | $0.00 |
| Q4 2019 | +18,851 | Add 62.20% | 49,156 | $9.74 |
| Q3 2019 | -186,971 | Reduce 86.05% | 30,305 | $8.02 |
| Q2 2019 | +217,276 | New Buy | 217,276 | $12.48 |
| Q1 2019 | -79,495 | Sold Out | 0 | $0.00 |
| Q4 2018 | +42,898 | Add 117.22% | 79,495 | $9.59 |
| Q3 2018 | -6,127 | Reduce 14.34% | 36,597 | $12.08 |
| Q2 2018 | +42,724 | New Buy | 42,724 | $15.61 |
| Q3 2017 | -12,332 | Sold Out | 0 | $0.00 |
| Q2 2017 | +12,332 | New Buy | 12,332 | $10.06 |
| Q1 2017 | -51,290 | Sold Out | 0 | $0.00 |
| Q4 2016 | +51,290 | New Buy | 51,290 | $4.97 |
| Q3 2016 | -72,981 | Sold Out | 0 | $0.00 |
| Q2 2016 | +56,031 | Add 330.57% | 72,981 | $5.45 |
| Q1 2016 | +16,950 | New Buy | 16,950 | $8.44 |
| Q4 2015 | -38,735 | Sold Out | 0 | $0.00 |
| Q3 2015 | -67,621 | Reduce 63.58% | 38,735 | $13.99 |
| Q2 2015 | +94,736 | Add 815.28% | 106,356 | $14.15 |
| Q1 2015 | -86,902 | Reduce 88.21% | 11,620 | $10.84 |
| Q4 2014 | +20,443 | Add 26.18% | 98,522 | $8.32 |
| Q3 2014 | +78,079 | New Buy | 78,079 | $5.96 |
Paul Tudor Jones's Amicus Therapeutics Investment FAQs
Paul Tudor Jones first purchased Amicus Therapeutics, Inc. (FOLD) in Q3 2014, acquiring 78,079 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Amicus Therapeutics, Inc. (FOLD) for 36 quarters since Q3 2014.
Paul Tudor Jones's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q4 2025, adding 900,000 shares worth $12.82 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 900,000 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $12.82 M.
As of the Q4 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Amicus Therapeutics, Inc. (FOLD) was 900,000 shares, as reported at the end of Q4 2025.